Second-line treatment for advanced small cell lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This study tests a new combination of two drugs for small cell lung cancer that has grown after the first round of treatment. The goal is to see if the combination can slow or stop the cancer and to look for markers that predict who benefits.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have small cell lung cancer confirmed by biopsy (not the mixed type).
- Your cancer must have progressed after receiving first-line chemotherapy with immunotherapy (such as a PD-1 or PD-L1 inhibitor).
- You must have at least one tumor that can be measured on imaging scans.
- You must be able to care for yourself (ECOG score 0 or 1) and have life expectancy of more than 12 weeks.
- Your organ functions (blood counts, liver, kidney) must be within acceptable ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs, including liposomal irinotecan, as the first treatment for extensive-stage small cell lung cancer. It aims to see if this combination can help control the cancer better than standard options.
This trial tests a new combination of two immunotherapy drugs plus chemotherapy as the first treatment for extensive-stage small cell lung cancer. It aims to see if this combination is safe and works better than standard care.
This study tests a type of immunotherapy called adebrelimab (a medicine that helps your immune system attack cancer) either alone or with other treatments in people with advanced solid tumors, including small cell lung cancer. The goal is to see if this approach can help control the cancer or improve outcomes.
This trial tests whether continuing a drug called adebrelimab (an immunotherapy) after standard treatment helps keep limited-stage small cell lung cancer from coming back. It compares adebrelimab with the usual approach of just watching and following up.
This trial is for people with limited-stage small cell lung cancer who have finished chemoradiation and still have small amounts of cancer DNA in their blood (called MRD-positive). The study tests a new treatment strategy after chemoradiation, and it may help reduce the chance of the cancer coming back.
This trial tests a combination of two drugs, adebrelimab and irinotecan liposome, with or without a third drug called famitinib, for people with extensive-stage small cell lung cancer that has progressed after initial treatment with immunotherapy. The goal is to see if this combination can help control the cancer.
Hear when a new Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.